224 related articles for article (PubMed ID: 38246477)
1. IUPHAR Review: New strategies for medications to treat substance use disorders.
Montoya ID; Volkow ND
Pharmacol Res; 2024 Feb; 200():107078. PubMed ID: 38246477
[TBL] [Abstract][Full Text] [Related]
2. Involving the pharmaceutical and biotech communities in medication development for substance abuse.
Gorodetzky CW; Grudzinskas C
Pharmacol Ther; 2005 Oct; 108(1):109-18. PubMed ID: 16038981
[TBL] [Abstract][Full Text] [Related]
3. National Institute on Drug Abuse (NIDA) research priorities to support the development of incentive-based treatments for substance use disorders.
Aklin WM; Herrmann ES
Prev Med; 2023 Nov; 176():107650. PubMed ID: 37524231
[TBL] [Abstract][Full Text] [Related]
4. A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction: An Editorial from a Legal Perspective.
Andraka-Christou B
Int Rev Neurobiol; 2016; 126():15-38. PubMed ID: 27055610
[TBL] [Abstract][Full Text] [Related]
5. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
Hennessy EA; Tanner-Smith EE; Finch AJ; Sathe N; Kugley S
Campbell Syst Rev; 2018; 14(1):1-86. PubMed ID: 37131375
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of dual substance abuse and dependence.
Kenna GA; Nielsen DM; Mello P; Schiesl A; Swift RM
CNS Drugs; 2007; 21(3):213-37. PubMed ID: 17338593
[TBL] [Abstract][Full Text] [Related]
7. Clinical neuroscience of addiction: similarities and differences between alcohol and other drugs.
Karoly HC; YorkWilliams SL; Hutchison KE
Alcohol Clin Exp Res; 2015 Nov; 39(11):2073-84. PubMed ID: 26414497
[TBL] [Abstract][Full Text] [Related]
8. Medication development for addictive disorders: the state of the science.
Vocci FJ; Acri J; Elkashef A
Am J Psychiatry; 2005 Aug; 162(8):1432-40. PubMed ID: 16055764
[TBL] [Abstract][Full Text] [Related]
9. Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use/misuse (TAPS) tool.
Wu LT; McNeely J; Subramaniam GA; Sharma G; VanVeldhuisen P; Schwartz RP
Contemp Clin Trials; 2016 Sep; 50():90-7. PubMed ID: 27444426
[TBL] [Abstract][Full Text] [Related]
10. Artificial Intelligence and Quantum Computing as the Next Pharma Disruptors.
Cova T; Vitorino C; Ferreira M; Nunes S; Rondon-Villarreal P; Pais A
Methods Mol Biol; 2022; 2390():321-347. PubMed ID: 34731476
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Implementing Effective Substance Abuse Treatments in General Medical Settings: Mapping the Research Terrain.
Ducharme LJ; Chandler RK; Harris AH
J Subst Abuse Treat; 2016 Jan; 60():110-8. PubMed ID: 26233697
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of substance use disorders in the neuroscience-based nomenclature (NbN).
Carton L; Nourredine M; Rolland B
Therapie; 2021; 76(2):127-136. PubMed ID: 33371988
[TBL] [Abstract][Full Text] [Related]
14. New medications for substance use disorders: challenges and opportunities.
Volkow ND; Skolnick P
Neuropsychopharmacology; 2012 Jan; 37(1):290-2. PubMed ID: 22157859
[TBL] [Abstract][Full Text] [Related]
15. Medications development: successes and challenges.
Vocci F; Ling W
Pharmacol Ther; 2005 Oct; 108(1):94-108. PubMed ID: 16083966
[TBL] [Abstract][Full Text] [Related]
16. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.
Grabowski J; Shearer J; Merrill J; Negus SS
Addict Behav; 2004 Sep; 29(7):1439-64. PubMed ID: 15345275
[TBL] [Abstract][Full Text] [Related]
17. The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.
Knudsen HK; Roman PM
J Stud Alcohol Drugs; 2014 May; 75(3):476-85. PubMed ID: 24766760
[TBL] [Abstract][Full Text] [Related]
18. Considerations in the Evaluation of Potential Efficacy of Medications for Alcohol and Drug Use Disorders: An Editorial.
Egli M; White DA; Acri JB
Int Rev Neurobiol; 2016; 126():1-14. PubMed ID: 27055609
[TBL] [Abstract][Full Text] [Related]
19. Contingency Management with pharmacologic treatment for Stimulant Use Disorders: A review.
Tardelli VS; Lago MPPD; Mendez M; Bisaga A; Fidalgo TM
Behav Res Ther; 2018 Dec; 111():57-63. PubMed ID: 30316027
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
